PTC Therapeutics PTCT Business Segments — Investment Income Interest
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's business segments — investment income interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's business segments — investment income interest?
- PTC Therapeutics (PTCT) reported business segments — investment income interest of $17.99M in Q1 2026.
- How has PTC Therapeutics's business segments — investment income interest changed year-over-year?
- PTC Therapeutics's business segments — investment income interest increased by 4.3% year-over-year, from $17.25M to $17.99M.
- What is the long-term trend for PTC Therapeutics's business segments — investment income interest?
- Over 2 years (2023 to 2025), PTC Therapeutics's business segments — investment income interest has grown at a 135.8% compound annual growth rate (CAGR), from $13.33M to $74.08M.
- What does business segments — investment income interest mean?
- This metric tracks the interest income generated from cash balances and short-term investments held by the life science segment. It reflects the company's ability to earn a return on its liquid assets while managing its treasury operations.